Last updated on April 2018

BAX 855 Previously Untreated Patient (PUP)

Brief description of study

The purpose of this study is to investigate safety, immunogenicity and hemostatic efficacy of PEGylated recombinant FVIII (BAX 855) in previously untreated patients (PUPs) < 6 years of age with severe hemophilia A (baseline FVIII level < 1%) and < 3 EDs to ADVATE, BAX 855 or plasma transfusion.

Clinical Study Identifier: NCT02615691

Contact Investigators or Research Sites near you

Start Over

Celine Kefurt

Chinese University Of Hong Kong
Shatin, Hong Kong
  Connect »

Celine Kefurt

The University of Hong Kong Queen Mary Hospital
Hong Kong, Hong Kong
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.